We read with great interest the Review by Carney and Freedland (Depression and coronary heart disease. Nat. Rev. Cardiol. http://dx.doi.org/10.1038/nrcardio.2016.181; 2016) 1 , in which the mechanisms linking depression and coronary heart disease are discussed. Specifically, this Review provides an update on biological and behavioural mechanisms, as well as potential interven tions to decrease the risk of cardiac events in patients with depression. However, we note the omission of discussion of the NLRP3 inflammasome complex from this Review.
The inflammasome has emerged as an unexpected sensor of metabolic danger and stress. Indeed, the inflammasome has been implicated in the development of major diseases such as gout, type 2 diabetes melli tus, and obesityinduced insulin resist ance, and other human pathologies such as cancer, asbestosis, and Alzheimer disease 2 . The inflammasome is a protein complex that comprises an intracellular sensor, typi cally a Nodlike receptor (NLR), the pre cursor procaspase 1, and the adaptor ASC. Inflammasome activation leads to the matur ation of caspase 1 and the processing of its substrates, IL1β and IL18 (REF. 3 ). Of all the NLRs, NLRP3 is activated by the most diverse array of danger signals.
The NLRP3 inflammasome has been widely studied in cardiovascular diseases (CVDs). NLRP3 regulation of wound healing in CVD has been discussed 4 . Furthermore, the NLRP3 inflammasome in the patho genesis of atherosclerosis has also been studied 5, 6 . Indeed, several studies have pro posed that inflammasome activation in cardio vascular tissues produces a variety of injurious actions, independent of the typi cal inflammation, suggesting noncanonical effects of inflammasome activation 7 . Our group has shown the participation of the NLRP3 inflammasome in the patho physiology of depression in both animal mod els and patients, as well as the effect of NLRP3 inhibition 8, 9 . The role of the inflamma some in depression and mood disorders has been widely reviewed 10 . The NLRP3 inflamma some is particularly activated after exposure to damage associated molecular patterns (known as DAMPs), such as extracellular ATP, excess glucose, ceramides, amyloids, urate, and cholesterol crystals, several of which increase CVD risk 11 and are also involved in mood disorders 10 . Accordingly, our preliminary studies demon strate that high fat diets or high sucrose diets induce NLRP3mediated cardiac damage accom panied by depressive symptoms (E.A.G. and M.D.C., unpublished data), showing a similar NLRP3dependent pathophysio logical pattern in both diseases (FIG. 1) . Furthermore, important processes that modulate inflammasome activation, such as autophagy and mitophagy 12 , are altered in CVD and depression 13, 14 . Finally, stress is an important physiologi cal process in depression and several sys temic diseases, including CVD 9, 15 . Molecular mechanisms of stress have been associated with several of the NLRP3 inflammasome pathways, including DAMPs. Psychological stress (an important depressive modulator) can activate the NLRP3 inflammasome, leading to the release of IL1β, which can contrib ute to the pathophysiology of sys temic diseases, such as diabetes mellitus and CVDs. Several NLRP3 inflammasome inhibitors are being developed and studied, and vari ous processes can inhibit its activation (FIG. 1) . In the coming years, therefore, we could see similar pharmacological treatments for depression and CVD.
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Elísabet Alcocer-Gómez and Mario D. Cordero Figure 1 | Inducers of the NLRP3 inflammasome related to depression and cardiovascular disease, and inhibitory strategies. Several damage-associated molecular patterns (known as DAMPs), such as ATP release, increased levels of cholesterol or glucose, increased levels of IL-1β, reactive oxygen species (ROS), and stress exposure, have been shown to induce NLRP3 inflammasome activation. Given that these potential NLRP3 inflammasome inducers have been associated with the pathophysiology of both depression and cardiovascular diseases, the use of the various NLRP3 inhibitors might be beneficial in both diseases. Nature Reviews | Cardiology 
